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OBJECTIVES: To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus
erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease
activity, laboratory findings and treatment.
METHODS: We included 67 consecutive childhood-onset systemic lupus erythematosus patients [61 women; median
age 18 years (range 11–31)], 55 first-degree relatives [50 women; median age 40 years (range 29–52)] and 47 age- and
sex-matched healthy controls [42 women; median age 19 years (range 6–30)]. The childhood-onset systemic lupus
erythematosus patients were assessed for clinical and laboratory systemic lupus erythematosus manifestations,
disease activity [Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)], cumulative damage [Systemic Lupus
International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index] and current drug use.
Serum IL-17 levels were measured by an enzyme-linked immunosorbent assay using commercial kits.
RESULTS: The median serum IL-17 level was 36.3 (range 17.36–105.92) pg/mL in childhood-onset systemic lupus
erythematosus patients and 29.47 (15.16–62.17) pg/mL in healthy controls (p=0.009). We observed an
association between serum IL-17 levels and active nephritis (p=0.01) and migraines (p=0.03). Serum IL-17 levels
were not associated with disease activity (p=0.32), cumulative damage (p=0.34), or medication use (p=0.63).
CONCLUSION: IL-17 is increased in childhood-onset systemic lupus erythematosus and may play a role in the
pathogenesis of neuropsychiatric and renal manifestations. Longitudinal studies are necessary to determine the
role of IL-17 in childhood-onset systemic lupus erythematosus.
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’ INTRODUCTION
Interleukin-17 (IL-17) is a potent pro-inflammatory cyto-
kine that is produced by activated T lymphocytes (1). Th17
cells are a subset of CD4+ T lymphocytes named after their
hallmark cytokine IL-17 (2), which represents the prototype
of a recently identified cytokine family comprising six
members (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F)
and five receptors (IL-17RA, IL-17RB, IL-17RC, IL-17RD,
IL-17RE). IL-17 production is stimulated by IL-23 (3).
IL-17 promotes inflammation by inducing local chemokine
and cytokine secretion (4) and is essential for the clearance
of certain pathogens such as bacteria and fungi. Moreover,
IL-17 has been linked to the instigation of immune-mediated
organ damage in the context of several autoimmune diseases
(3). The frequency of IL-17-producing T cells is increased in
the peripheral blood of adult systemic lupus erythematosus
(SLE) patients (4,6), and IL-17 production is abnormal in SLE
patients (4–11). IL-17 levels are increased in adult SLE sera
and correlate with disease activity (9, 12–15).
SLE is a heterogenic autoimmune inflammatory disease
characterized by a wide spectrum of clinical manifestations and
abnormal production of high-titer autoantibodies directed
towards nuclear autoantigens (5,7,8). Although the pathogen-
esis of SLE is not completely clear, genetic, environmental and
hormonal factors play key roles in susceptibility and hetero-
geneous clinical manifestations (5). Childhood-onset SLE (cSLE)
has a clinically different phenotype than adult-onset SLE (9).
For instance, cSLE patients have increased kidney and centralDOI: 10.6061/clinics/2015(05)01
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nervous system (CNS) involvement (16). These differences in
the frequencies of clinical manifestations could be due to
differences in the proinflammatory cytokine milieu in cSLE (9).
Only one previous study has analyzed IL-17 levels in cSLE
(9). In this study of 40 cSLE patients, increased serum IL-17
levels were observed compared with healthy controls (9). An
association between increased IL-17 levels and active disease,
cutaneous manifestations and hematological manifestations
has been described (9).
Therefore, the aim of our study was to determine the
serum IL-17 levels in a large cSLE cohort, their first-degree
relatives and healthy controls. Additionally, we evaluated
the association of IL-17 with disease activity, laboratory
findings and treatment features.
’ METHODS
Subjects
Sixty-seven consecutive cSLE patients followed at the
Pediatric Rheumatology Unit of the State University of
Campinas were invited to participate in this cross-sectional
study. Patients were included in the present study if they
(i) fulfilled at least four of the American College of Rheumatol-
ogy (ACR) criteria (17), (ii) were younger than 16 years of age at
disease onset, and (iii) had a follow-up duration of at least
6 months. Forty-seven first-degree relatives were included in
this study. Fifty-five healthy controls without a history of any
chronic disease (including a personal history of autoimmune
diseases) were included as the control group.
The healthy controls were matched for age, sex and demo-
graphic background. This study was approved by the ethics
committee at our institution, and written informed consent was
obtained from each participant and/or legal guardian.
Clinical, laboratory and treatment features
The medical histories and clinical and serological features
of each patient were reviewed in medical charts. The
variables included in this database were the disease onset
(defined as the age at which the first symptoms clearly
attributable to SLE occurred), age at diagnosis (defined as the
age at which the patients fulfilled four or more of the 1982
revised criteria for the classification of SLE (17)), and follow-up
time (defined as the time from disease onset until July 2011).
All clinical manifestations and laboratory findings were
recorded on the day of blood withdrawal. Active nephritis
was diagnosed on the basis of the renal items of the SLE
Disease Activity Index (SLEDAI) (18): proteinuria exceeding
0.5 g/24 hours and active urinary sediment [urinary casts,
hematuria (X5 red cells/high power field [HPF]) and pyuria
(X5 leucocytes/HPF) in the absence of urinary tract infections].
Nephrotic syndrome was defined as proteinuria in excess
of 3 g/day. Hematological abnormalities were ascribed to
lupus only in the absence of bone-marrow suppression
(leukopenia o4000 cells/mm3, thrombocytopenia o100,000
cells/mm3, and hemolytic anemia). We also assessed the
presence of malar rash, discoid lesions, subacute cutaneous
lesions, cutaneous vasculitis, photosensitivity, oral ulcers,
arthritis, and serositis. Neurological and psychiatric involve-
ment was defined according to the ACR guidelines (19).
The treatment prescribed at the time of blood withdrawal and
any adverse events related to medication use were recorded.
Doses of oral and parenteral corticosteroids were analyzed and
converted to the equivalent doses of prednisone.
Antinuclear antibodies (ANA) were measured by indirect
immunofluorescence using HEp-2 cells as the substrate andwere
regarded as positive if higher than 1:40. Double-stranded DNA
(dsDNA) antibodies were determined by indirect immunofluor-
escence using Crithidia as the substrate and were considered
positive if higher than 1:10. Precipitating antibodies to extractable
nuclear antigens (ENA), including Ro (SSA), La (SSB), and Sm,
were detected using a standardized enzyme-linked immunosor-
bent assay (ELISA) method and were considered positive if
higher than 1:80. IgG- and IgM-isotype anticardiolipin antibodies
(aCL) were measured using an ELISA (20). Lupus anticoagulant
(LA) activity was detected by coagulation assays in platelet-free
plasma obtained by double centrifugation, following the
recommendation of the subcommittee on LA of the Scientific
and Standardization Committee of the International Society of
Thrombosis and Homeostasis (21). These measurements were
performed twice at a 12-week interval.
Diseases Activity/Cumulative Damage Evaluation
Disease activity was measured by the SLEDAI 2000
(SLEDAI-2K) (18). The SLEDAI-2K comprises 24 weighted
items grouped into 9 domains, representing organ systems.
SLEDAI scores range between 0 and 105. Scores greater than
3 were considered active disease (22).
Cumulative SLE-related damage was identified in all
patients using the Systemic Lupus International Collaborat-
ing Clinics (SLICC)/ACR Damage Index (SDI) at the time of
blood withdrawal. SDI scores range from 0 to 47. Damage
was considered to be present if scores were X 1 (23).
Mood and anxiety evaluation
All subjects completed the Beck Depression Inventory
(BDI) (24) and Beck Anxiety Inventory (BAI) (25) at study
entry. For patients under sixteen years old, the Children’s
Depression Inventory (CDI) was applied. These scales
comprise 21 items, each describing a common symptom of
depression/anxiety. The respondent is asked to rate how
much he or she has been bothered by each symptom over the
past month on a 4-point scale, ranging from 0 to 3. The items
are summed to obtain a total score that can range from 0
to 63. The cutoffs used for the BDI are as follows: 0–13:
no/minimal depression; 14–19: mild depression; 20–28:
moderate depression; and 29–63: severe depression. For the
BAI, the cutoffs are as follows: 0–7: no/minimal level of
anxiety; 8–15: mild anxiety; 16–25: moderate anxiety; and
26–63: severe anxiety. The cutoff used for the CDI was 17.
IL-17 assay
Blood samples were collected from all participants,
allowed to clot for 30 min at room temperature, and
centrifuged at 3000 rpm for 15 min. Separated sera were
kept in aliquots at  80°C until assayed. None of the samples
were taken during an episode of acute or chronic infection
(20). Serum IL-17 levels were measured by ELISA, using
commercially available kits from R&D Systems (London,
UK), in accordance with the manufacturer’s instructions. The
detection range for IL-17 was 31.2–2000 pg/ml, with a
sensitivity of 15 pg/ml (human IL-17 kit).
Statistical analysis
All statistical analyses were performed using the Systat
12 software and SPSS Statistics 17.0 software, and the results
are given as the median and range. The Kruskal-Wallis test
was used to compare cytokine levels between groups.
Spearman’s correlation was used to correlate continuous
variables (e.g., cytokine levels and SLEDAI, SDI, BDI and
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BAI scores). Cytokine levels and categorical variables were
compared using the Mann–Whitney U test. The level of
significance was set to po0.05.
’ RESULTS
Demographics
We included 67 consecutive cSLE patients. Sixty-one (91.04%)
were female, with a median age of 18 years (range 11–31). The
median disease duration was 5 years (range 0–26). We included
55 first-degree relatives with a median age of 40 years (range
29–52) (Table 1). The control group comprised 47 healthy
volunteers (42 women) with a median age of 19 (range 6–30).
The patients and healthy controls were statistically comparable
in terms of age and sex (Table 1).
Clinical, laboratory and treatment features
At the time of study entry, 35 (52.2%) cSLE patients had
active disease (SLEDAI43), with a median SLEDAI score of 8
(range 4–24). Patients with inactive disease [N=32 (47.8%)] had
a median SLEDAI score of 0 [(range 0–2)]. Active nephritis
(35.8%), new malar rash (8.9%), new alopecia (4.5%), cutaneous
vasculitis (4.5%) and migraine (4.5%) were the most frequently
observed clinical manifestations (Table 2).
At the time of blood withdrawal, 6 (8.9%) patients were
not taking any medication. Fifty-nine (88%) patients were
receiving prednisone, 38 (57%) were receiving hydroxychlor-
oquine, and 26 (39%) patients were receiving other immu-
nosuppressive drugs.
With regard to mood and anxiety disorders, 41 (61%) cSLE
patients showed no anxiety symptoms, 16 (24%) had mild
symptoms, 6 (9%) had moderate symptoms and 4 (6%) had
severe symptoms. For depression, 59 (88%) cSLE patients
showed no depression symptoms, 5 (8%) had mild depres-
sion, 1 (1%) had moderate depression, and 2 (3%) had severe
depression (Table 3).
IL-17 assay
The median serum IL-17 levels were 36.3 (range
17.36–105.92) pg/mL in the cSLE patients and 29.47
(15.16–62.17) pg/mL in the healthy controls (p=0.009). No
differences were found between the serum levels of the
patients and first-degree relatives (median 32.22 pg/mL,
range: 18.93–88.54 pg/mL; p=0.41) or between the healthy
controls and first-degree relatives (p=0.11) (Figure 1).
Serum IL-17 levels were significantly increased in cSLE
patients with migraines (p=0.03) and with active nephritis
(p=0.01). However, serum IL-17 levels were not associated
with disease activity (p=0.32), cumulative damage (p=0.34),
anxiety (p=0.42) or depression (p=0.42). Serum IL-17 levels
did not differ between patients with and without immuno-
suppressant use (p=0.63). Upon analyzing each individual
medication, no associations were observed.
Table 1 - Demographic and clinical characteristics and IL-17 levels of the patients and controls included in the study.
Childhood-onset SLE patients (N=67) First-degree relatives (N=55) Healthy controls (N=47)
Sex
Female 61 (91.04%) 50 (90.90%) 42 (89.36%)
Age (years) 18 (range 11–31 ) 40* (range 29–52 ) 19 (range 6–30 )
Disease duration (years) 5 (range 0–25) ----- -----
SLEDAI 4 (range 0–24) ----- -----
Active disease N=35 8 (range 4–24)
Inactive disease N=32 0 (range 0–2)
SDI 0 (range 0–3) ----- -----
Treatment ----- -----
No medication 6 (8.9%)
Prednisone 61 (91.1%)
Dose (mg median/range) 15 (0–60)
Hydroxychloroquine 37 (55.2%)
Immunosuppressive drugs 26 (38.8%)
Azathioprine 16 (23.8%)
Cyclophosphamide 3 (4.4%)
Cyclosporine 5 (7.7%)
Methotrexate 1 (1.5%)
Mycophenolate mofetil 1 (1.5%)
Clinical finding
Nephritis 24 (35.8%)
Rash malar 6 (8.9%)
Alopecia 3 (4.5%)
Vasculitis 3 (4.5%)
Migraine 3 (4.5%)
IL-17 (pg/ml) 36.3* (17.36–105.92) 32.22 (18.93–88.54) 29.47* (15.16–62.17)
*pp0.05
Table 2 - Serum IL-17 levels compared with the main clinical
manifestations.
Clinical Manifestation Median (pg/mL) IQR P-value
Malar Rash 0.5
Yes (N=6) 37.11 10.28
No (N=61) 36.30 12.66
Alopecia 0.1
Yes (N=3) 29.47 12.26
No (N=64) 36.30 12.26
Cutaneous manifestation 0.2
Yes (N=8) 33.16 12.93
No (N=59) 36.30 12.78
Nephritis 0.01*
Yes (N=24) 36.86 16.41
No (N=43) 21.31 11.60
Vasculitis 0.9
Yes (N=4) 39.49 12.55
No (N=63) 35.27 12.55
*pp0.05
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’ DISCUSSION
Recently, Th17 cells have been identified as a new T cell
subset; the signature cytokines secreted by Th17 cells include
IL-17A, IL-17F, IL-21, and IL-22 (2,10,11). This array of cytokines
can stimulate B lymphocytes and set off local inflammation and
tissue injury, leading to SLE pathogenesis. Evidence supporting
the role of IL-17 in SLE pathogenesis has been found in human
lupus as well as in an animal model (2,26).
IL-17 and other Th17 cytokines have been most commonly
described as proinflammatory cytokines due to their expres-
sion in the lesions of patients with chronic inflammatory
diseases and their role in inducing inflammation (27,28). A
significant fraction of the IL-17 produced in SLE patients
derives from double-negative (DN) TCR-ab+CD4CD8 T
cells (26). DN T cells represent a small T cell subset in healthy
individuals. These cells are expanded in the peripheral
blood of SLE patients and produce proinflammatory chemo-
kines and cytokines, including IL-17, IFN-g, and IL-1b (29).
We observed an increase in serum IL-17 levels in cSLE patients
compared with healthy controls. Our data also corroborate
some studies in adult SLE patients (6,10,12–15, 27,28) and
cSLE patients (9).
The association between IL-17 levels and disease activity
remains controversial (9,10,12–15). Although some studies
observed a positive association, we and other studies have
found no association between IL-17 levels and disease activity
(27,28). These diverse findings may be explained by the
heterogeneity of clinical and laboratory manifestations in SLE,
the different sample size in the above-mentioned studies and
variations in the principle and sensitivity of the ELISA tests.
We detected higher IL-17 levels in SLE patients with nephritis.
Our data are in agreement with previous studies suggesting that
IL-17 could contribute to the pathogenesis of kidney involve-
ment in SLE patients (13,28,30). Support for the pathogenic role
of IL-17 derives from the fact that IL-17-producing T cells have
been observed in the kidneys of patients with lupus nephritis
(29). IL-17 is mostly produced by CD4+, CD8+, CD4/CD8 ,
g/d T cells, and Th17 cells. In human lupus nephritis,
IL-17-expressing T cells migrate to the kidneys and contribute
to inflammatory processes (28,29,31). However, a recent study
with cSLE patients did not demonstrate an association between
IL-17 and nephritis (9). These findings may be due to the smaller
number of patients included or to a different disease duration.
Studies in animal models have shown that T cells
expressing IL-17 infiltrate the kidneys of SLE patients. A
significant proportion of these cells are CD3+CD4-CD8- DN
T cells (26). Additionally, the authors showed that DN T cells
from MRL/lpr mice express high levels of IL-17 and that as
the disease progressively worsens, IL-17 and IL-23 receptor
expression increases in lymphocytes (26).
In another study, IL-23R–deficient lupus-prone C57BL/
6–lpr/lpr mice displayed decreased numbers of CD3+
CD42CD82 cells and IL-17A–producing cells in the lymph
nodes and produced less anti-DNA antibodies. Additionally,
clinical and pathological measures of lupus nephritis were
abrogated. This experimental study clearly shows the
importance of IL-23R–mediated signaling in the develop-
ment of lupus nephritis and proposes the use of appropriate
biologics to treat the disease (32).
A recent study demonstrated that Th17 cells react to CNS
autoantigens and manifest a higher migratory capability to
the CNS parenchyma compared WITH other T cell sub-
populations due to their ability to penetrate the blood-brain
barrier (11). CNS involvement is frequently observed in cSLE
patients (33). In our study, we observed an association
between increased IL-17 levels and migraines. To date, no
studies in the literature have explored this association.
Previous studies have demonstrated an association between
mood disorders and IL-17 levels (34,35). The first study
observed increased IL-17 levels in patients with rheumatoid
arthritis and anxiety, and IL-17 levels were independently
associated with higher anxiety scores (34). Another study
observed increased IL-17 levels in patients with mood disorders
compared with healthy controls (35). In our study, no
association between IL-17 and mood disorders was observed.
However, we evaluated mood disorders with a self-evaluation
questionnaire of symptoms of depression/anxiety, which is not
a diagnostic tool; this may have influenced the negative results.
A recent study with a cSLE cohort observed a correlation
between IL-17 levels and disease activity and cutaneous and
hematological manifestations (9). We did not observe any of
these findings in our cohort. This can be explained by the
different genetic background, different disease duration and
different sample size (we had a larger number of patients).
Similarly to previous studies, we did not observe
differences in IL-17 levels according to the use of immuno-
suppressants (27,36).
SLE is an autoimmune disease, and although genetic
susceptibility contributes to its inheritance, environmental
factors are also important disease triggers (37). Previous
studies have shown that healthy SLE family members have
a significantly higher risk of developing SLE or other
Table 3 - Serum IL-17 levels compared with the main
neuropsychiatric manifestations.
Neuropsychiatric Manifestation Median (pg/mL) IQR P-value
BAI 0.4
Yes (N=26) 36.86 10.90
No (N=41) 38.05 11.67
BDI 0.4
Yes (N=8) 36.58 9.29
No (N=59) 36.88 11.85
Migraine 0.03*
Yes (N=3) 36.58 13.55
No (N=64) 28.33 12.12
*pp0.05
Figure 1 - Serum IL-17 levels observed in the three groups
included in this study.
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autoimmune diseases (37,38). However, the IL-17 levels in
first-degree relatives have never been studied. In our study,
we observed that the IL-17 levels in first-degree relatives
were elevated compared with controls, but this value was
not significant.
In summary, IL-17 may play a role in the pathogenesis of
neuropsychiatric and renal manifestations in cSLE patients.
Longitudinal studies with regular serum analysis are
necessary to determine the role of IL-17 in cSLE.
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